STERIS plc

STERIS plc (STE) — Investment Memo

🐂 The Bull Case (Warren's voice)

• The "Toll Bridge" Moat: STERIS doesn't sell a luxury; they sell clinical necessity. A hospital cannot operate a single surgical suite without sterilization. This is the ultimate "utility" within the healthcare ecosystem.
• The Razor-Blade Lock-in: The capital equipment is the hook, but the outsourced sterilization services and consumables are the perpetual annuity. Once a hospital integrates STERIS protocols into their regulatory compliance workflow, switching is not a financial decision—it's a risk management nightmare.
• Financial Hygiene: Management is behaving like owners. Slashing debt by $1.2B in a single year proves they value a clean balance sheet over vanity growth.
• Cash Divergence: FCF is consistently outstripping Net Income ($0.8B vs $0.6B). The business is generating more cold hard cash than the accountants are allowed to report.
• Attractive Range: This becomes a "no-brainer" if we can capture the business at a significant discount to its intrinsic value, allowing us to ride the inevitable expansion of the global surgical volume.

🐻 The Bear Case (Charlie inverts)

“Show me where I’ll die and I won’t go there.”

• The "Disposable" Death Spiral: The greatest structural threat is the shift toward single-use, disposable surgical instruments. If the industry moves from "sterilize and reuse" to "use and toss," the entire STERIS capital base and service moat becomes a collection of expensive, useless relics.
• Margin Fragility: Revenue grew from $2.6B to $5.5B, yet net margins are a "roller coaster." Growth without margin stability is just getting bigger for the sake of being bigger. This suggests a lack of pricing power in certain segments.
• The ROE Problem: An ROE moving from 3.9% to 9.3% is an improvement, but it's still mediocre. A truly exceptional business doesn't struggle for a decade to hit double digits.
• Most Likely Failure: The move toward single-use disposables. Timeframe: 5–10 years. If the "blade" becomes a disposable plastic tool made by a competitor, the "razor" (STERIS) is irrelevant.

💰 Valuation & Margin of Safety

Based on DCF: $27.9B Total Valuation

• Intrinsic value estimate: $283.53 per share.
• 25% margin of safety entry: $212.65 (Conservative—protects against margin volatility).
• 50% margin of safety entry: $141.77 (Buffett's ideal—makes the "disposable" risk irrelevant).
• Current Status: Fairly valued to slightly overvalued relative to the DCF. We are paying for the growth, not getting a bargain.

Verdict: WATCH

The moat is durable, but the ROE is too lean for a full-scale Berkshire bet at current prices. We wait for a market dislocation to bring the price toward the $212 level. We don't buy quality at any price; we buy quality at a price that ensures we can't be wrong.